"While this type of therapy is most commonly associated with cancer treatment, doctors are increasingly using it to address another high-risk condition: autoimmune conditions. That's what Lauran Neergaard reports in a new article published by the Associated Press.The article points to the work of the University of Erlangen-Nuremberg's Dr. Georg Schett, who began using CAR-T cell therapy to treat patients with conditions like lupus. One of Dr. Schett's patients, the Associated Press reports, has been in remission for almost six years."
"The authors of a paper published in Bone Marrow Transplantation last year observed that using CAR-T cell therapy to treat autoimmune conditions "may represent a paradigm shift in the management of these challenging conditions." That said, the authors also raised one concern as potentially affecting this research: the high costs of such treatment, something the Associated Press's article also brings up. Still, it's a promising start to a potentially massive change in treating certain medical conditions."
CAR-T cell therapy transformed treatment of relapsed/refractory B-cell malignancies and multiple myeloma and has shown evidence against some solid tumors. Clinicians are increasingly applying CAR-T to high-risk autoimmune conditions, including lupus, myositis, and scleroderma. Georg Schett at the University of Erlangen-Nuremberg used CAR-T to treat lupus patients; one patient remains in remission for almost six years. A patient with both lupus and lymphoma received CAR-T and experienced treatment for both illnesses. Some researchers describe CAR-T for autoimmune disease as a potential paradigm shift in management, but high treatment costs pose a major barrier. Early clinical experiences are promising but cost and broader validation remain challenges.
Read at InsideHook
Unable to calculate read time
Collection
[
|
...
]